Mesalazine - Dr Falk Pharma

Drug Profile

Mesalazine - Dr Falk Pharma

Alternative Names: AJG501; Apriso; Mesalamine 0.375g extended-release capsules (Apriso) - Salix Pharmaceuticals; Mesalamine granules - Salix Pharmaceuticals; Salofalk

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Dr Falk Pharma
  • Developer Ajinomoto; Dr Falk Pharma; Salix Pharmaceuticals
  • Class Aminosalicylic acids; Anti-inflammatories; Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Lipoxygenase-cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Ulcerative colitis
  • Phase II Colorectal cancer; Ulcerative proctitis
  • Discontinued Diverticulitis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Aug 2015 Dr. Falk Pharma completes a phase II trial in Ulcerative proctitis in Germany (Rectal) (NCT01966783)
  • 01 Jul 2015 Dr Falk Pharma completes a phase II trial in Colorectal cancer (Prevention) in Netherlands (EudraCT2011-001815-29)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top